Neurotropic therapy in patients with hearing impairment with chronic cerebral ischemia: an open, uncontrolled study

Aim. To identify sensorineural hearing loss and ear noise in patients with chronic cerebral ischemia on an outpatient basis, and to evaluate the experience of using combined neurotropic therapy in this category of patients.
Material and methods. The study included 50 patients with chronic cerebral ischemia (CIG), with hearing impairments of varying degrees, ear noise, vestibular, cerebro-asthenic syndrome, and who had an outpatient appointment with a neurologist. All patients underwent a scale assessment of VAS – a visually analog scale of ear noise, VAS-G – a visually analog scale of dizziness, THI – a subjective scale for assessing the severity of ear noise, MFI-20 – a scale of severity of asthenia. All patients in the study group were treated with сellex on the background of complex therapy in the form of two courses of therapy with an interval of 20 days. Before the start of treatment, after the end of the first and second courses of treatment, testing was carried out according to appropriate scales and questionnaires, as well as otoneurological and audiological examinations.
Results. In the study group of patients, a varying degree of sensorineural hearing loss was detected, as well as a high comorbid background, with most patients experiencing subjective noise of varying intensity, as well as moderately pronounced vestibular syndrome and cerebral asthenic syndrome. After the complex treatment, there was a statistically significant subjective improvement in hearing and speech intelligibility, as well as a statistically significant decrease in indicators on the scales of subjective assessment of noise and dizziness, a decrease in general, physical and mental asthenia. The most statistically significant difference in positive changes was noted after a second course of therapy.
In conclusion, the positive results of this study can be considered a decrease in the severity and severity of symptoms of sensorineural hearing loss, which achieved statistically significant improvement after the second course of therapy, a decrease in the manifestations of ear noise, a decrease in asthenia, a decrease in the feeling of dizziness and instability against the background of neurotropic therapy with сellex. In this situation, preference should be given to drugs with a multimodal mechanism of action, potentially affecting various levels of disorders in vascular pathology of the brain, including the auditory analyzer, as well as contributing to the processes of neuroplasticity of the brain.

1. Левина М.А. Этиопатогенетические аспекты нейросенсорных нарушений слуха. Российский вестник оториноларингологии 2015;80(6):77–81. DOI: 10.17116/otorino201580677-81 Levina M.A. The etiopathogenetic aspects of sensorineural impairment of hearing. Rossiiskii vestnik otorinolaringologii = Russian Bulletin of Otorhinolaryngology 2015;80(6):77–81. (In Russ.). DOI: 10.17116/otorino201580677-81

2. Парфенов В.А., Антоненко Л.М. Нейросенсорная тугоухость в неврологической практике. Неврология, нейропсихиатрия, психосоматика 2017;9(2):10–4. Parfenov V.A., Antonenko L.M. Sensorineural hearing loss in neurological practice. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2017;9(2):10–4. (In Russ.).

3. Berjis N., Moeinimehr M., Hashemi S.M. Endothelial dysfunction in patients with sudden sensorineural hearing loss. Adv Biomedl Res 2016;5:5. DOI: 10.4103/2277-9175.174978

4. Носкова В.В., Храбриков А.Н. Дисфункция эндотелия как патогенетический фактор нейросенсорной тугоухости. Российский оториноларингологический вестник 2024;89(1):21–7. Noskova V.V., Khrabrikov A.N. Endothelial dysfunction as a pathogenetic factor of sensorineural hearing loss. Rossiyskiy otorinolaringologicheskiy vestnik = Russian Bulletin of Otorhinolaryngology 2024;89(1):21–7. (In Russ.). DOI: 10.17116/otorino20248901121

5. Sarant J., Harris D., Mangoni A.A. Mcevoy М. Hearing loss and circulating markers of endothelial dysfunction. Hearing J 2018;71(5):8–9. DOI: 10.1097/01.HJ.0000533798.71848.74

6. Кунельская Н.Л., Левина Ю.В., Байбакова Е.В. Субъективный шум в ухе: современные тенденции и перспективы. Вестник оториноларингологии 2019;84(6):54–60. Kunelskaya N.L., Levina Yu.V., Baibakova E.V. Subjective ear noise: current trends and prospects. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology 2019;84(6):54–60. (In Russ.). DOI: 10.17116/otorino20198406154

7. Золотова Т.В., Дубинская Н.В., Давыдова А.П. Современные аспекты патогенетического лечения нейросенсорной тугоухости. Вестник оториноларингологии 2020;85(3):6–10. Zolotova T.V., Dubinskaya N.V., Davydova A.P. Modern aspects of pathogenetic treatment of sensorineural hearing loss. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology 2020;85(3):6–10. (In Russ.). DOI: 10.17116/otorino2020850316

8. Танашян М.М., Домашенко М.А., Максимова М.Ю. Современная нейропротекция в комплексном лечении пациентов в остром и раннем восстановительном периоде ишемического инсульта. Нервные болезни 2017;(3):18–22. Tanashyan M.M., Domashenko M.A., Maksimova M.Yu. Modern neuroprotection in the complex treatment of patients in the acute and early recovery period of ischemic stroke. Nervnye bolezni = Nervous Diseases 2017;(3):18–22. (In Russ.).

9. Бельская Г.Н., Крылова Л.Г., Соколов М.А., Измайлов И.А. Возможности коррекции речевых нарушений в остром периоде ишемического инсульта с использованием нейропротекторной терапии. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(9-2):60–3. DOI: 10.17116/jnevro20151159260-63

10. Камчатнов П.Р., Абусуева Б.А., Ханмурзаева С.Б. и др. Результаты оценки эффективности препарата Целлекс у пациентов с заболеваниями мелких сосудов. Журнал неврологии и психиатрии им. С.С. Корсакова 2023;123(1):67–74.

11. Абусуева Б.А., Евзельман М.А., Камчатнов П.Р., Умарова Х.Я. Применение Целлекса у пациентов с хронической ишемией головного мозга и умеренными когнитивными нарушениями. Нервные болезни 2016;(2):29–34. Abusueva B.A., Evzelman M.A., Kamchatnov P.R., Umarova Kh.Ya. The use of Cellex in patients with chronic cerebral ischemia and moderate cognitive impairment. Nervnye bolezni = Nervous Diseases 2016;(2):29–34. (In Russ.).

12. Baumgartner J.E., Baumgartner L.S., Baumgartner M.E. et al. Progenitor. cell therapy for acquired pediatric nervous system injury: Traumatic brain injury and acquired sensorineural hearing loss. Stem Cells Transl Med 2021;10(2):164–80. DOI: 10.1002/sctm.20-0026

13. Mady О.М., Ezzat W.F., Askoura А.М. Stem cell therapy in sensorineural hearing loss: a systematic review. Egypt J Otolaryngol 2023;39(1);153. DOI: 10.1186/s4363-023-00452-w

14. Щукин И.А., Кольцов И.А., Фидлер М.С., Чубыкин В.И. Эффективность и безопасность применения препарата Целлекс для лечения пациентов с когнитивными нарушениями с хронической ишемией головного мозга – результаты многоцентрового рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова 2023;123(5):108–16. DOI: 10.17116/jnevro2023123051108

15. Прокопенко С.В., Шанина Е.Г., Петрова М.М., Можейко Е.Ю. Нейрорепарация: современные взгляды на проблему. Фарматека 2014;(13):24–8. Prokopenko S.V., Shanina E.G., Petrova M.M., Mozheyko E.Yu. Neurorepilation: modern views on the problem. Farmateka = Pharmateca 2014;(13):24–8. (In Russ.).

16. Кулеш А.А., Шестаков В.В. Постинсультные когнитивные расстройства и возможности терапии препаратом Целлекс. Журнал неврологии и психиатрии им. С.С. Корсакова 2016;116(5):38–45. DOI: 10.17116/jnevro20161165138-42 Kulesh A.A., Shestakov V.V. Post-stroke cognitive disorders and possibilities of therapy with Cellex. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2016;116(5):38–45. (In Russ.). DOI: 10.17116/jnevro20161165138-42